Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Efficacy and safety of antibody-drug conjugates in gastrointestinal malignancies: A systematic review and meta-analysis of phase I-III trials.

Sawyer Bawek, Azza Sarfraz, Mrinalini Ramesh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15035

e15035 Background: Antibody-drug conjugates (ADCs) represent a promising targeted therapy class for GI malignancies, with...

SPECTRUM: Phase II study of tislelizumab plus pemetrexed in patients with relapsed or refractory (R/R) primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS)—The Korean Cancer Study Group LY22-07.

Jung Sun Kim, Gyeong-Won Lee, Myungwon Lee et al. Jun 01, 2026 pp. 2009-2009 10.1200/jco.2026.44.16_suppl.2009

2009 Background: Primary DLBCL of the CNS is a rare extranodal lymphoma confined to the CNS. Despite standard high-dose me...

Rethinking risk: Disparities and genetic testing outcomes from a novel public-facing cancer prevention program.

Jessica Russo, Lee Ifhar, Helen Nunez et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13607

e13607 Background: Identifying individuals at high risk for cancer is central to effective prevention and early detection....

Rezvilutamide (Rez) versus bicalutamide (Bic) plus androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): 5-year outcomes of the phase 3 CHART trial.

Dingwei Ye, Bo Dai, Weijie Gu et al. Jun 01, 2026 pp. 5090-5090 10.1200/jco.2026.44.16_suppl.5090

5090 Background: In the CHART trial, Rez plus ADT significantly improved radiographic progression-free survival (rPFS) and...

Clinical characterization and survival of patients (pts) with <i>PIK3CA</i> -mutated metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of four randomized trials.

Arndt Stahler, Julia Anna Theresia Stahler, Dominik Paul Modest et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15541

e15541 Background: We aimed to characterize pts with PIK3CA MUT mCRC and to estima...

Comparison of a highly sensitive, tumor-informed Illumina whole genome sequencing research assay and a tumor-informed bespoke whole exome sequencing assay for molecular residual disease detection in CheckMate-77T (NCT 04025879).

Jonathan Beer, Li Liu, Khai Luong et al. Jun 01, 2026 pp. 8591-8591 10.1200/jco.2026.44.16_suppl.8591

8591 Background: In CheckMate 77T (NCT 04025879), nivolumab showed clinically meaningful improvements in event free surviv...

Nodulomics: Histopathologic and genomic heterogeneity among multiple malignant pulmonary nodules sampled by robotic-assisted bronchoscopy.

Jamie Rowell, Yupeng Liu, Rohan Bhargava et al. Jun 01, 2026 pp. 8049-8049 10.1200/jco.2026.44.16_suppl.8049

8049 Background: Multiple pulmonary nodules (MPN) pose significant challenges for accurate staging of non-small cell lung...

Scalable knowledge distillation for pancreatic cancer diagnosis: Real-time ResNet-based stage stratification with global deployment feasibility.

Abdul basit Khan, Elangovan Krishnan, Shankar Biswas et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16412

e16412 Background: Pancreatic cancer remains one of the deadliest cancers, with a 5-year survival below 12%. Early-stage d...

MRI-derived tumor burden and growth rate as translational biomarkers: Head-to-head comparison with RECIST and ctDNA in tebentafusp-treated metastatic uveal melanoma.

Toulsie Ramtohul, Xavier-Louis Jasawant, Jose Luis Sandoval et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21584

e21584 Background: Tebentafusp improves survival in metastatic uveal melanoma (mUM), yet RECIST v1.1 responses are uncommo...

A matched-adjusted indirect comparison (MAIC) of nogapendekin alfa inbakicept-pmln plus bacillus Calmette–Guérin (NAI+BCG) and pembrolizumab in patients with BCG-unresponsive non–muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) ± papillary disease.

Christopher Michael Pieczonka, Connie Ly, Hoora Moradian et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16619

e16619 Background: Several FDA approved treatments offer bladder-sparing options for patients with BCG-unresponsive NMIBC...

A randomized controlled pilot study of aromatherapy to reduce anxiety and pain during bone marrow aspiration and biopsy.

Krisstina Gowin, Ali Derakhshani, Maggie Goodson et al. Jun 01, 2026 pp. 12140-12140 10.1200/jco.2026.44.16_suppl.12140

12140 Background: Bone marrow aspiration and biopsy (BMAB) is associated with substantial anxiety and pain among patients...

Prognostic impact of cancer stem cell markers on survival outcomes in solid tumors: A systematic review and meta-analysis.

Salma Younas, Sweta Sahu, Sravani Bhavanam et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15187

e15187 Background: Cancer stem cell (CSC) markers have been implicated in tumor aggressiveness and treatment resistance. P...

Autologous natural killer cell infusion as consolidation therapy after first-line chemoradiotherapy for limited-stage small-cell lung cancer: A randomized, controlled, open-label, single-center phase II clinical study.

Jiuwei Cui, Xiao Chen, Rilan Bai et al. Jun 01, 2026 pp. 8013-8013 10.1200/jco.2026.44.16_suppl.8013

8013 Background: Small-cell lung cancer (SCLC) grows rapidly, is aggressive, has a poor prognosis, and tends to recur afte...

BNT324-03: Phase 3, randomized, open-label trial of BNT324/DB-1311, a B7H3 ADC, versus docetaxel in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC).

Johann S. de Bono, Benjamin Garmezy, Dingwei Ye et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps5137

TPS5137 Background: B7H3 is highly expressed in various human cancers, including mCRPC, and overexpression is associated w...

Impact of pre-existing autoimmune disease on clinical outcomes in patients treated with bispecific monoclonal antibodies for B-cell lymphomas.

Nanda Krishnan Siva, Shanawar Ali Waris, Shilajeet Ray et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19008

e19008 Background: Bispecific antibodies (BsAbs), including glofitamab, epcoritamab, and mosunetuzumab, are FDA-approved f...

Efficacy and safety outcomes of biweekly compared with standard triweekly gemcitabine/nab-paclitaxel in advanced pancreatic cancer: A systematic review and meta-analysis.

Victor Andres Castillo, Vanessa Pamela Salolin-Vargas, Huber Padilla-Zambrano et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16405

e16405 Background: Pancreatic cancer remains one of the most lethal malignancies, with a rising incidence and persistently...

STRATOS-P clinical model for prognosis and selection of patients with metastatic hormone sensitive prostate cancer (mHSPC) for intermittent therapy.

Martin W. Schoen, Joshua Gruber, Jason M. Doherty et al. Jun 01, 2026 pp. 5106-5106 10.1200/jco.2026.44.16_suppl.5106

5106 Background: Current trials use prostate-specific antigen (PSA) response of ≤0.2 ng/mL at 6-12 months as a prognostic...

The impact of high body-mass index on cancer mortality in the United States: An emerging public health challenge.

Charbel Fadi Matar, Jennifer Kate Beckerman, Joyce Chen et al. Jun 01, 2026 pp. 10626-10626 10.1200/jco.2026.44.16_suppl.10626

10626 Background: Obesity prevalence has increased markedly in the United States, yet the contribution of high body-mass i...

Rates of metachronous colorectal cancer or secondary Lynch syndrome–related cancers in patients with non-metastatic colorectal cancer.

Emily M. Russell, Sarah Nielsen Young, Erica M. Vaccari et al. Jun 01, 2026 pp. 3648-3648 10.1200/jco.2026.44.16_suppl.3648

3648 Background: Lynch syndrome (LS) increases metachronous colorectal cancer (CRC) risk up to 5-fold, while extended rese...

SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, <i> BRAF <sup>V600E</sup> </i> metastatic colorectal cancer (mCRC).

Van K. Morris, Sarah Colby, Scott Kopetz et al. Jun 01, 2026 pp. 3504-3504 10.1200/jco.2026.44.16_suppl.3504

3504 Background: BRAF V600E mutation...

Enhanced financial assistance intervention for unmet essential needs: A prospective pilot study to improve timely cancer treatment completion.

Justin Michael Barnes, Shannon Jinxia Jiang, Kimberly J. Johnson et al. Jun 01, 2026 pp. 11078-11078 10.1200/jco.2026.44.16_suppl.11078

11078 Background: Unmet essential needs, such as food, transportation, and housing insecurity, can create barriers to time...

PACT-chemo: Improving chemotherapy flow, safety, and value through physician–pharmacist EHR activation at SSMC, a tertiary hospital in the Middle East.

Ammar Oday Abdaljalil Abdaljalil, Aydah Al-Awadhi, Hossameldin Hazaa et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23317

e23317 Background: Chemotherapy order activation is a major ambulatory infusion bottleneck and a key point to intercept hi...

BCG at home: A first-in-kind pilot trial of home-based intravesical Bacillus Calmette-Guérin delivery for high-risk non-muscle-invasive bladder cancer.

Daniel Lee, Scott A. Soefje, Danielle Fidyk et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13615

e13615 Background: Bacillus Calmette-Guérin (BCG) remains the standard intravesical therapy for high-risk non-muscle-invas...

Survival outcomes with modern first-line systemic therapy in advanced hepatocellular carcinoma: A systematic review and meta-analysis.

Abdul Ghani Iqbal, Maryam Ali, Sidra Anwar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16218

e16218 Background: First-line systemic therapy for advanced hepatocellular carcinoma (HCC) has evolved from tyrosine kinas...

Neurological adverse events related to immune checkpoint inhibitors in cancer treatment: A systematic review and meta-analysis of clinical trials.

Thuraya Al-Sayegh, Ahmad Toubasi Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14569

e14569 Background: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment with significant improvements i...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page